Akums Launches Rabeprazole and Levosulpiride SR Capsules For GIT Disorders

Akums Drugs & Pharmaceuticals Ltd declared the launch of Rabeprazole + Levosulpiride SR capsules. This new formulation, which was approved by the Drug Controller General of India (DCGI), aims to provide patients with better relief from disorders of the gastrointestinal tract (GIT) disorders.

GERD, or gastro-oesophageal reflux infection, is a crippling condition described by the reflux of stomach contents into the throat, prompting inconvenient side effects and potential complications.  With GERD often dubbed as chronic acid reflux, has a negative impact on quality of life and increases the risk of serious health problems like stomach and esophageal cancer.

Rabeprazole sodium, a potent antisecretory compound, targets the H+ and K+ ATPase on the surface of gastric parietal cells to selectively inhibit gastric acid secretion. It has been shown to be effective in treating GERD as well as gastric and duodenal ulcers. In addition to rabeprazole, the levo-enantiomer of sulpiride, levosulpiride, has significant antiemetic and central antidopaminergic activity. It is useful in gastroenterology because its peripheral anti-dopaminergic action regulates the motor activity of the upper digestive tract.

Arushi Jain, Director, Akums Drugs & Pharmaceuticals Ltd, commented, “We are excited to introduce a solution for patients suffering from GERD and related gastrointestinal disorders. GERD diagnosis and treatment rely on symptom management and acid suppression therapies. Our Rabeprazole + Levosulpiride SR Capsules aim to offer an effective remedy, ease symptoms, enhance gastrointestinal function, and booste patients' overall well-being. Levosulpiride offers rapid relief and better healing outcomes with fewer side effects, elevating the overall treatment experience."